← Back to Home

Cutting Off Bacteria’s Vitamin Supply: Novel Antibiotic Candidates Advance into Animal Infection Models

The research team targeted ECF transporters, which existing antibiotics have not exploited, preventing bacteria from obtaining the vitamins they need to survive. The candidate compounds have shown activity in multiple infection models, but drug distribution, safety, and resistance assessments still stand between them and use in humans.

By SURL BioNews

The most challenging aspect of the antimicrobial resistance crisis is not only that older drugs are gradually losing effectiveness, but also that most antibiotics repeatedly attack only a small number of familiar bacterial mechanisms. A team associated with Germany’s Helmholtz Centre for Infection Research has proposed another approach: instead of directly disrupting cell-wall formation or protein synthesis, it blocks the channels through which bacteria import vitamins, depriving them of the nutrients needed to sustain growth and infection.

The research focuses on “energy-coupling factor transporters” (ECF transporters). Many bacteria use these membrane proteins to actively take up essential vitamins from their environment. Human cells do not have the same system, so it may offer a more selective target. However, the absence of the same target represents only a theoretical safety advantage and cannot replace subsequent toxicology, metabolism, and human tolerability studies.

Two studies published in the Journal of Medicinal Chemistry address drug-like properties and mechanism of action, respectively. The team began with existing ECF inhibitors and modified the molecules through structure–activity relationship studies. Early compounds degraded too quickly in liver microsome tests, while improved versions combined better metabolic stability and solubility with activity against ECF transporters and multiple Gram-positive bacteria. The researchers also observed rapid bactericidal effects in experiments involving Enterococcus faecalis.

The evidence for these compounds is no longer limited to the laboratory dish. Data from a University of Groningen paper show that the better-performing candidates were effective in infection models involving greater wax moth larvae and zebrafish. Separate coverage of the same development also reported that one candidate reduced the bacterial load in the lungs to about one-tenth that of the untreated group in a mouse model of Streptococcus pneumoniae lung infection. These results support the ability of the drugs to act in living organisms, but the infection conditions, doses, and drug exposure in different models cannot be directly translated into efficacy in humans.

The research team also used CRISPR interference to reduce the expression of ECF-related genes in Streptococcus pneumoniae, after which the bacteria became more sensitive to the compounds. When additional copies of the genes were introduced, sensitivity decreased, providing genetic evidence that the drugs do indeed target the ECF system. The target genes were also highly conserved among the clinical Streptococcus pneumoniae strains examined in the study. No resistant variants emerged during the experiments, but the sample size and observation period were limited, so this cannot yet establish that bacteria would have difficulty evolving an escape route.

This work remains at the preclinical candidate-development stage. The researchers must next improve potency and drug concentrations at infection sites, while clarifying in vivo metabolism, organ toxicity, the therapeutic window, and longer-term resistance risks. ECF transporters are attractive because they differ from the main targets of existing antibiotics. The real test is whether this “cutting off the supply” strategy can be translated—without harming the host—into a drug that can be manufactured consistently, delivered effectively, and withstand clinical validation.

References

  1. Helmholtz Centre for Infection Research
  2. University of Groningen Research Portal
  3. Phys.org